Telratolimod is primarily used in the field of immunotherapy, particularly as a potent agonist for toll-like receptor 7 (TLR7). It is being investigated for its ability to stimulate the immune system, making it a potential candidate for treating various cancers. By activating TLR7, it enhances the body's innate immune response, promoting the production of cytokines and other immune-modulating molecules that can help in attacking tumor cells. Additionally, Telratolimod is being explored for its potential use in combination with other therapies, such as checkpoint inhibitors, to improve their efficacy in cancer treatment. Its application is also being studied in the context of antiviral therapies, leveraging its immune-stimulating properties to combat viral infections.